Altamira Therapeutics Ltd. Selling, General and Administrative Expense
Altamira Therapeutics Ltd. (CYTOF) reported Selling, General and Administrative Expense of $3.20 million for the 12-month period ending 2024-12-31, per its 20-F filed 2025-04-30.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:SellingGeneralAndAdministrativeExpense · last filed 2025-04-30
CHF
| Period end | Selling General And Administrative Expense 12 month | Selling General And Administrative Expense 12 month as first filed |
|---|---|---|
| 2023-12-31 | 3.14M CHF 20-F/A · filed 2024-04-22 | |
| 2022-12-31 | 3.40M CHF 20-F/A · filed 2024-04-22 | 3.64M CHF 20-F · filed 2023-05-16 |
| 2021-12-31 | 3.67M CHF 20-F/A · filed 2024-04-22 | 4.95M CHF 20-F · filed 2023-05-16 |
| 2020-12-31 | 2.59M CHF 20-F · filed 2023-05-16 |
USD
| Period end | Selling General And Administrative Expense 12 month |
|---|---|
| 2024-12-31 | $3.20M 20-F · filed 2025-04-30 |
| 2023-12-31 | $3.49M 20-F · filed 2025-04-30 |
| 2022-12-31 | $3.56M 20-F · filed 2025-04-30 |